U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07508982) titled 'Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML' on March 30.
Brief Summary: This is a phase Ib/II study that aims to investigate the safety, tolerability and explore the efficacy of BCL- XL inhibition in participants with high-risk AML.
Study Start Date: Sept. 01, 2026
Study Type: INTERVENTIONAL
Condition:
AML
Intervention:
DRUG: Azacitidine
Given by IV
DRUG: APG1252
Given by IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Disclaimer: Curated by HT Syndication....